FATE Fate Therapeutics, Inc.
$2.06▼ -2.61%
Healthcare
Other
Volume 1.46M
Avg Volume (10D) 1.33M
Key Metrics & Fundamentals
Market Cap
$246.23M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.95 - 3.23
% vs 50 MA
-11.62%
% vs 200 MA
6.16%
RSI-14
43.3
MACD Histogram
+0.0100
Beta (1Y vs SPY)
2.11
Free Cash Flow
-$23.51M
Gross Rev
$2.08M
Gross Profit
$2.08M
EBITDA
-$28.35M
COGS
–
Operating Exp
$33.22M
Operating Income
-$31.13M
EBIT
-$31.13M
Pretax Income
-$30.16M
Net Income
-$30.16M
EPS (Diluted)
-0.25
Price & Volume History
Loading chart…
Recent News
Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026
GlobeNewswire · Oct 26, 2026 7:00 AM ET
Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies
GlobeNewswire · Oct 12, 2026 7:00 AM ET
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 2, 2026 7:00 AM ET
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
GlobeNewswire · Oct 1, 2026 7:00 AM ET
Sector Update: Healthcare Stocks Edge Higher Premarket Friday
MT Newswires · Sep 25, 2026 9:19 AM ET
Fate Therapeutics Receives $15 Million Grant for Lupus Treatment Trial
MT Newswires · Sep 25, 2026 8:03 AM ET
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
GlobeNewswire · Sep 25, 2026 7:00 AM ET
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
GlobeNewswire · Sep 16, 2026 7:00 AM ET
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting
GlobeNewswire · Sep 9, 2026 7:00 AM ET
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
GlobeNewswire · Sep 3, 2026 7:00 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See FATE's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.